MFG
CTKB icon

Merit Financial Group’s Cytek Biosciences CTKB Stock Holding History

Merit Financial Group’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,398
Closed -$71.7K – 2377
2026
Q1 		$71.7K Buy
+16,398
New +$77.4K ﹤0.01% 2041
2025
Q3 		– Sell
-11,103
Closed -$37.8K – 1811
2025
Q2 		$37.8K Buy
+11,103
New +$37K ﹤0.01% 1674

Other funds holding CTKB

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
NAM
NorthCrest Asset Manangement Plymouth, Minnesota $3.89B AUM 40.33% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
DCM
Davis Capital Management Jacksonville, Florida $169M AUM 22.99% 1-Year Est. Return

Merit Financial Group's CTKB Position: Q2 2026 in Review

Merit Financial Group sold out of Cytek Biosciences (CTKB) in Q2 2026, closing a stake of 16,398 shares — an estimated $71.7K sold.

Merit Financial Group first reported a position in CTKB in Q2 2025 and held it in 2 quarters. The position peaked at $71.7K in Q1 2026. 9 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Merit Financial Group reported no remaining Cytek Biosciences position as of Q2 2026 after selling out during the quarter.
  • Merit Financial Group sold 16,398 Cytek Biosciences shares in Q2 2026, an estimated $71.7K.
  • Merit Financial Group first reported a position in Cytek Biosciences in Q2 2025 and held it in 2 quarters.
  • Merit Financial Group's Cytek Biosciences position peaked at $71.7K in Q1 2026.
  • 9 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Merit Financial Group's 13F filing for Q2 2026, filed 17 Jul 2026.